Articles
Drug Science publish regular articles that analyse developments in drug science and policy to highlight areas of improvement based on evidence
Author Petter Grahl Johnstad Published July 25, 2022 Abstract Researchers have associated cannabis use with risk for psychosis, cognitive impairment, and traffic accident. However, this review shows that the association between moderate cannabis use and psychosis is no stronger, and often considerably weaker, than the corresponding association for moderate tobacco use.…
- July 25, 2022
Author MaryKate Duska, Jared M. Rhoads, Elizabeth C. Saunders, Tracy Onega Published July 25, 2022 Objective To examine the relative changes in opioid overdose mortality rates between states that have and have not adopted naloxone co-prescribing laws. Methods We performed a synthetic control analysis. National Vital Statistics data for the years…
- July 25, 2022
Get Project Twenty21 Updates via Email Our Project Twenty21 monthly updates have changed. From now on, we will be incorporating the medical cannabis news (previously included in our T21 mailout) into the Drug Science newsletter which goes out around the first Tuesday of every month. This means that from next month you…
- July 12, 2022
Diamorphine-assisted treatment is the prescription and provision of hygienic, medical-grade diamorphine to patients in a clinical set-up - patients attend a clinic and are dosed by a clinician once or twice a day depending on individual needs.Drug-related deaths in the UK have risen significantly over the past 10 years, with a…
- July 11, 2022
Author Cathal T Gallagher Published July 11, 2022 Abstract The Misuse of Drugs Regulations 2001 (MDRs) create exemptions to the offences of possession, production, supply, and administration of controlled drugs (CDs), which are necessary to allow healthcare professionals to treat patients without rendering themselves liable to prosecution for various offences under…
- July 11, 2022
The Drug Enforcement Agency listens to psychedelic experts
By Professor David Nutt and James Bunn The Drug Enforcement Agency (DEA) recently withdrew a proposal to ban five psychedelic substances: 4-Hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alphamethyltryptamine (5-MeO-AMT), N-Isopropyl-5-Methoxy-N-Methyltryptamine (5-MeO-MiPT), N,N-Diethyl-5-methoxytryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT). Earlier this year, the DEA proposed that these substances ought to be moved to schedule 1 (the most restrictive…